- Home
- DLXY vs APVO Comparison
DLXY vs APVO Comparison
Compare DLXY & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLXY | APVO |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | DLXY | APVO |
|---|---|---|
| Price | $0.42 | $4.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 86.8K | 28.2K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.50 |
| 52 Week High | $7.00 | $13.11 |
Technical Indicators
Market Signals| Indicator | DLXY | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 35.17 | 55.20 |
| Support Level | N/A | $4.29 |
| Resistance Level | $1.07 | $5.22 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 7.48 | 84.27 |
Price Performance
Historical ComparisonAbout DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.